134 related articles for article (PubMed ID: 38324904)
1. Impact of and interplay between proton arc therapy and range uncertainties in proton therapy for head-and-neck cancer.
Tattenberg S; Liu P; Mulhem A; Cong X; Thome C; Ding X
Phys Med Biol; 2024 Feb; 69(5):. PubMed ID: 38324904
[No Abstract] [Full Text] [Related]
2. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study.
Liu G; Li X; Qin A; Zheng W; Yan D; Zhang S; Stevens C; Kabolizadeh P; Ding X
Radiat Oncol; 2020 Jan; 15(1):21. PubMed ID: 32000817
[TBL] [Abstract][Full Text] [Related]
3. PTV-based VMAT vs. robust IMPT for head-and-neck cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
Rojo-Santiago J; Korevaar E; Perkó Z; Both S; Habraken SJM; Hoogeman MS
Radiother Oncol; 2023 Sep; 186():109729. PubMed ID: 37301261
[TBL] [Abstract][Full Text] [Related]
4. Comparison of linear and nonlinear programming approaches for "worst case dose" and "minmax" robust optimization of intensity-modulated proton therapy dose distributions.
Zaghian M; Cao W; Liu W; Kardar L; Randeniya S; Mohan R; Lim G
J Appl Clin Med Phys; 2017 Mar; 18(2):15-25. PubMed ID: 28300378
[TBL] [Abstract][Full Text] [Related]
5. Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - From a fixed beam line to an arc.
Amstutz F; Krcek R; Bachtiary B; Weber DC; Lomax AJ; Unkelbach J; Zhang Y
Radiother Oncol; 2024 Jan; 190():109973. PubMed ID: 37913953
[TBL] [Abstract][Full Text] [Related]
6. Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
de Jong BA; Korevaar EW; Maring A; Werkman CI; Scandurra D; Janssens G; Both S; Langendijk JA
Radiother Oncol; 2023 Jul; 184():109670. PubMed ID: 37059337
[TBL] [Abstract][Full Text] [Related]
7. Robust optimization to reduce the impact of biological effect variation from physical uncertainties in intensity-modulated proton therapy.
Bai X; Lim G; Grosshans D; Mohan R; Cao W
Phys Med Biol; 2019 Jan; 64(2):025004. PubMed ID: 30523932
[TBL] [Abstract][Full Text] [Related]
8. Statistical evaluation of worst-case robust optimization intensity-modulated proton therapy plans using an exhaustive sampling approach.
Yang Z; Li H; Li Y; Li Y; Chang Y; Li Q; Yang K; Wu G; Sahoo N; Poenisch F; Gillin M; Zhu XR; Zhang X
Radiat Oncol; 2019 Jul; 14(1):129. PubMed ID: 31324257
[TBL] [Abstract][Full Text] [Related]
9. Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy.
Cubillos-Mesías M; Troost EGC; Lohaus F; Agolli L; Rehm M; Richter C; Stützer K
Br J Radiol; 2020 Mar; 93(1107):20190573. PubMed ID: 31778315
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the effect of setup uncertainty reduction and adaptation to geometric changes on normal tissue complication probability using online adaptive head and neck intensity modulated proton therapy.
Lalonde A; Bobić M; Sharp GC; Chamseddine I; Winey B; Paganetti H
Phys Med Biol; 2023 May; 68(11):. PubMed ID: 37164020
[No Abstract] [Full Text] [Related]
11. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
[TBL] [Abstract][Full Text] [Related]
12. Proton range uncertainty reduction benefits for skull base tumors in terms of normal tissue complication probability (NTCP) and healthy tissue doses.
Tattenberg S; Madden TM; Gorissen BL; Bortfeld T; Parodi K; Verburg J
Med Phys; 2021 Sep; 48(9):5356-5366. PubMed ID: 34260085
[TBL] [Abstract][Full Text] [Related]
13. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy.
Ding X; Li X; Zhang JM; Kabolizadeh P; Stevens C; Yan D
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1107-1116. PubMed ID: 27869083
[TBL] [Abstract][Full Text] [Related]
14. Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region.
Stuschke M; Kaiser A; Abu Jawad J; Pöttgen C; Levegrün S; Farr J
Radiat Oncol; 2013 Jun; 8():145. PubMed ID: 23773560
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers.
Liu W; Frank SJ; Li X; Li Y; Park PC; Dong L; Ronald Zhu X; Mohan R
Med Phys; 2013 May; 40(5):051711. PubMed ID: 23635259
[TBL] [Abstract][Full Text] [Related]
16. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.
van der Laan HP; van de Water TA; van Herpt HE; Christianen ME; Bijl HP; Korevaar EW; Rasch CR; van 't Veld AA; van der Schaaf A; Schilstra C; Langendijk JA;
Acta Oncol; 2013 Apr; 52(3):561-9. PubMed ID: 22708528
[TBL] [Abstract][Full Text] [Related]
17. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer.
Inoue T; Widder J; van Dijk LV; Takegawa H; Koizumi M; Takashina M; Usui K; Kurokawa C; Sugimoto S; Saito AI; Sasai K; Van't Veld AA; Langendijk JA; Korevaar EW
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):661-9. PubMed ID: 27681763
[TBL] [Abstract][Full Text] [Related]
18. Introducing Proton Track-End Objectives in Intensity Modulated Proton Therapy Optimization to Reduce Linear Energy Transfer and Relative Biological Effectiveness in Critical Structures.
Traneus E; Ödén J
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):747-757. PubMed ID: 30395906
[TBL] [Abstract][Full Text] [Related]
19. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
Moreno AC; Frank SJ; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Williamson TD; Holliday EB; Phan J; Blanchard P
Oral Oncol; 2019 Jan; 88():66-74. PubMed ID: 30616799
[TBL] [Abstract][Full Text] [Related]
20. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
